We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Affitech to Play key Role in Major EU Embryonal Tumor Pipeline Project


Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Affitech to Play key Role in Major EU Embryonal Tumor Pipeline Project"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 

Affitech has announced that it has been selected to participate in the new European Union E.E.T. Pipeline project to identify fully human therapeutic antibody candidates for Embryonal Tumors (ET) by using its antibody discovery platform.

The E.E.T. Pipeline project is a multidisciplinary consortium of leading European institutions and SMEs (Small and Medium Enterprise), which the EU is funding with ? 4 million for developing methods of diagnosis and treatment for ET.

Such methods would be based on gene expression profiling of tumors and would include other post-genomic investigative technologies.

The EU has taken this initiative since Embryonal Tumors are classified as orphan diseases, but they do not comprise large enough markets to justify the costs of drug development for the pharmaceutical industry.

"Affitech has become involved in the E.E.T. Pipeline project because of the current absence of efficient targeted therapeutics for ET," commented Dr Martin Welschof, CEO of Affitech.

"We are excited about the opportunity of participating in the project, and  the possibility of contributing to coordinated progress in the treatment and diagnosis of ET."

Dr. Bjorn Cochlovius, Afftech’s Director of R&D said, "We have utilized our highly efficient antibody libraries and high throughput screening systems to create a pipeline of multiple therapeutic cancer antibody candidates for both ourselves and our commercial partners."

"Therefore, we are delighted to be able to utilize our experience with several internationally recognised research groups involved in E.E.T. Pipeline consortium in identifying potential antibody therapeutics for this devastating childhood disease."

Advertisement